医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Saama Receives Two Awards at 2018 Big Data & Analytics Converge for Innovation and Industry Excellence

2018年02月05日 AM11:30
このエントリーをはてなブックマークに追加


 

MUMBAI, India

Saama Technologies, Inc., a leading clinical analytics company, has received not one, but two awards at the Big Data & Analytics Converge 2018. The company received the “Innovative Technology of the Year” award as well as the “Excellence in Industry Application” award in the B2B Sector.

This was the fifth edition of the data and analytics event, which showcases Big Data use cases and techniques that drive the greatest business value. The awards, presented at the Big Data & Analytics Converge, recognize achievements and innovations in the field of Big Data & Analytics across industries.

These two latest awards continue Saama’s run of recognition, which started last year when the company’s Life Science Analytics Cloud (LSAC) was hailed by PM360 as one of the most innovative Products of 2017. Life Science Analytics Cloud is a suite of solutions by Saama Technologies which integrates multiple sources of structured and unstructured data to offer relevant analytics results. The solution is cloud-based and has pre-built capabilities for data ingestion, integration, and analysis, allowing companies to set up the platform faster. With Life Science Analytics Cloud, a company can start generating real-time and comprehensive business insights within weeks, while reducing costs and strain on various resources, leading to better patient and business outcomes.

Saama Technologies is a recognized name in the life science and pharmaceutical industry for being one of the leaders in applying data analytics technology to clinical data. The company has shown deep expertise in leveraging artificial intelligence (AI) and using machine learning to develop solutions that can be applied to clinical data. Saama’s LSAC suite of solutions is able to integrate complex data from disparate sources and run analytics over them to derive timely and useful insights.

“We at Saama have long been committed to developing technological solutions and applying our wide knowledge of the industry to help pharmaceutical organizations speed up their clinical trials and reach the market faster. To be recognized for our effort, of course, gives us immense joy,” said Rakesh Rajendran, VP, Head of India Operations. “We are happy to accept this award from the people associated with Converge, as it is a platform that recognizes real-life business impact of technological innovation in Big Data & Analytics.”

About Saama

Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences, and the Global 2000. We are singularly focused on driving fast, flexible, impactful business outcomes for our clients through data and analytics. Our unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management, and Big Data technologies. We blend manual and disconnected initiatives into a well-aligned roadmap facilitating the client’s journey from strategy through solution implementation.

About Big Data, Analytics & Insights Summit

Big Data & Analytics Converge is a platform where Big Data use cases and techniques with the greatest business value are showcased. With an emphasis on real life implementation of Big Data technologies, this practical business forum provides bold vision from leading innovators across the data-driven spectrum to help delegates gain fresh insights and strategic momentum to grow and leverage data for competitive advantage.

The 2018 edition was at Taj Lands End, Mumbai, India on February 1st.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180204005077/en/

CONTACT

Saama Technologies
Crystal Black, 408-371-1900
crystal.black@saama.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品工業によるシャイアーの買収案を日本の公正取引委員会が承認
  • 武田拟收购Shire plc获得日本公平交易委员会批准
  • James Till教授因干细胞发现而荣获2018年度江户川Niche奖
  • Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
  • Brightree发布面向居家医疗器械的首个患者App